With 17 years of pioneering research, Restem has built a leading IP portfolio and end-to-end manufacturing capabilities to produce highly potent, off-the-shelf cellular therapeutics at scale. Restem-L, our ULSC platform demonstrated clinical benefit in patients with Idiopathic Inflammatory Myopathies (IIM), reducing the need for steroids and earning FDA Fast Track and Orphan Drug Designations as we prepare for Phase 2/3 clinical trials.